Merged with ID6554.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6555
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 February 2026 | Please note that this appraisal has been merged with ID6554 and will continue under ID6554. The new title for ID6554 is "Baloxavir marboxil for treating and preventing influenza in people 3 weeks to 11 years" |
| 05 February 2026 | Discontinued. Merged with ID6554. |
| 15 October 2025 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 21 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual